Publications by authors named "Andreas Pinter"

Claim this Profile
R
Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database.
Andreas Pinter, Marcus Schulte, Nils Kossack, Marc Pignot, Michael Schultze

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial.
Robert Bissonnette, Ronald Vender, Andreas Pinter, Leanne M Stanley, Carrie R Houts

J Dermatolog Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany.
Luise Heinrich, Thomas Birkner, Susanne Abraham, Sascha Gerdes, Tatjana Honstein, Andreas Pinter

Skin Health Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.
Joseph F Merola, Lyn Guenther, Charles Lynde, Kim A Papp, Lawrence Charles Parish, Andreas Pinter

J Eur Acad Dermatol Venereol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.
David Strawn, James G Krueger, Robert Bissonnette, Kilian Eyerich, Laura K Ferris, Andreas Pinter

JCI Insight· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.
Robert Bissonnette, Jennifer Soung, Adelaide A Hebert, Andrew E Pink, Andreas Pinter

N Engl J Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Andreas Pinter, Alan Brnabic, Emanuele Trovato, Lluís Puig, Jose-Manuel Carrascosa

Dermatol Ther (Heidelb)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vilobelimab to improve clinical outcomes of moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: Results of the SHINE double-blind, placebo-controlled randomised trial.
Evangelos J Giamarellos-Bourboulis, Gregor B E Jemec, Errol P Prens, Niels C Riedemann, Isabell Otto, Andreas Pinter

Br J Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison.
Sonja Ständer, Andreas Pinter, Firas G Hougeir, Patricia Guyot, Yingxin Xu

Dermatol Ther (Heidelb)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period.
Richard B Warren, Mark Lebwohl, Diamant Thaçi, Melinda Gooderham, Andreas Pinter

Br J Dermatol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study.
Matthias Augustin, Esther Serra-Baldrich, Julien Seneschal, Susanne Grond, Anastasia Lampropoulou, Andreas Pinter

Adv Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials.
Andreas Pinter, Jordi Galván, Frank Freischläger

Dermatol Ther (Heidelb)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
Ana Maria Giménez-Arnau, Andreas Pinter, Wiebke Sondermann, Ziad Reguiai, Richard Woolf

Lancet· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High content imaging shows distinct macrophage and dendritic cell phenotypes for psoriasis and atopic dermatitis.
Nathalie J Behr, Sandra Pierre, Tanja Ickelsheimer, Nicole Ziegler, Sonja Luckhardt, Andreas Pinter

Sci Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reflections on chronic hand eczema - Authors' reply.
Robert Bissonnette, Richard B Warren, Andreas Pinter, Tove Agner, Melinda Gooderham

Lancet· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of a Disease-specific Outcomes Tool for the Assessment of Patient Benefits of Treatment for Hidradenitis Suppurativa: the PBI-HS.
Natalia Kirsten, Matthias Augustin, Christine Blome, Janine Topp, Richard Schwager, Andreas Pinter

Acta Derm Venereol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical Study.
Stephanie Dauth, Ann Christina Foldenauer, Konstantin Hallmann, Christina Kunz, Anke König, Andreas Pinter

Dermatology· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study).
Dagmar Wilsmann-Theis, Selina Patt, Andreas Pinter, Sascha Gerdes, Nina Magnolo

JAAD Int· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Richard B Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J Korman, Andreas Pinter

Dermatol Ther (Heidelb)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Richard B Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J Korman, Andreas Pinter

Dermatol Ther (Heidelb)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
Joseph F Merola, Alice B Gottlieb, Andreas Pinter, Boni Elewski, Melinda Gooderham

Dermatol Ther (Heidelb)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims data.
Andreas Pinter, Ahmed M Soliman, Karina C Manz, Valeria Weber, Paul Ludwig

Clin Exp Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening of psoriatic arthritis by dermatologists - a German nationwide survey.
Andreas Pinter, Matthias Hofmann, Roland Kaufmann, Jutta Müller-Stahl, Anke König

J Dtsch Dermatol Ges· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial.
Laure Gossec, Laura C Coates, Dafna D Gladman, Jacob A Aelion, Jitendra Vasandani, Andreas Pinter

Ann Rheum Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.
Matthias Augustin, Alice B Gottlieb, Mark Lebwohl, Andreas Pinter, Richard B Warren

Dermatol Ther (Heidelb)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis